Rothschild & Co has upgraded Kenvue Inc (KVUE) from Neutral to Buy as of September 25, 2025. The current price stands at $16.41.
This upgrade reflects a more optimistic outlook on Kenvue's prospects. Such decisions reflect improved fundamentals, better-than-expected business performance, or heightened confidence in the company’s strategic direction.
Kenvue is a consumer health company based in Summit, New Jersey, employing 22,000 full-time staff. The company, which went public on May 4, 2023, manufactures and sells a diverse portfolio of healthcare products, including well-known brands like Tylenol, Neutrogena, and Listerine. Kenvue operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.
As of November 20, 2025, Kenvue boasts a market cap of $30.8 billion, with a P/E ratio of 21.47 and an EPS of 0.74. The company has a notable dividend yield of 516.8%. Upcoming earnings are expected to be reported on February 4, 2026, with an EPS estimate of $0.25 and revenue of $3.8 billion.
Analyst ratings and price targets provide professional insights based on extensive research and financial models. However, these assessments are based on assumptions that may not always come to fruition. Investors should consider various factors, including company fundamentals and market conditions, rather than relying solely on analyst opinions. Analyst ratings can evolve as new information emerges, and differing views may exist among analysts regarding the same company.